#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302

ORLANDO, FL, USA (UroToday.com) - Presented by Johann Sebastian De Bono, Matthew Raymond Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Eric Jay Small, Neal D. Shore, Karim Fizazi, Peter De Porre, Thian San Kheoh, Jinhui Li, Mary Beth Todd, Thomas W. Griffin, and Charles J. Ryan at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA

 

gu cancers 2015 debono poster

 

The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK; Harvard Medical School and Massachusetts General Hospital Cancer Center, Boston, MA; University of Montréal, Montréal, Québec, Canada; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Radboud University Medical Centre, Nijmegen, The Netherlands; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC; Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Janssen Research & Development, Beerse, Belgium; Janssen Research & Development, San Diego, CA; Johnson & Johnson Medical China, Shanghai, China; Janssen Global Services, Raritan, NJ; Janssen Research & Development, Los Angeles, CA

Click HERE to read related content